Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Walter Reed Army Medical Center20 enrolled

Overview

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Healthy

Interventions

Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better. Exclusion Criteria: * Patients not meeting above stated age criteria * Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study) * History of serious ocular, neurological, cardiovascular disease * History of severe systemic disease * History of arrhythmias or high blood pressure * Patients currently taking any type of ocular or systemic medications except multivitamins. * Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Locations (1)

Walter Reed Army Medical Center

Washington D.C., District of Columbia, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.